Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder. Finding effective treatments and interventions for ASD still requires a great deal of research. At Ace Therapeutics, we are committed to providing innovative preclinical solutions for autism spectrum disorder research. Our advanced technology and expertise in the field of psychiatric disorders allows us to provide our clients with reliable animal models and the potential impact on autism drug discovery and development.
Autism spectrum disorders (ASD) include autism, Asperger's syndrome, childhood disintegrative disorder, and unspecified forms of pervasive developmental disorder. the number of children diagnosed with ASD is continuing to climb. ASD cannot be prevented, but treatment options are available. Early diagnosis and intervention are most effective and can improve behavior, skills, and language development. Treatment options may include behavioral therapy, communication therapy, educational therapy, family therapy, and medication. There are no medications available to improve the core signs that impede ASD, but specific medications may help control symptoms.
Fig. 1 Potential influences of autism spectrum disorder (ASD). (Zhuang, H.; et al., 2024)
Pathophysiologic Mechanism Research Services of Autism Spectrum Disorders
ASD arises from a complex interplay of genetic and environmental factors, leading to changes in brain structure and function that manifest as behavioral abnormalities. Ace Therapeutics utilizes animal models, genetic approaches, and histological studies to help clients delve into the underlying mechanisms that lead to genetic associations in ASD. Furthermore, we integrate animal models with our platform technologies to assist our clients in identifying crucial physiological and metabolic irregularities associated with ASD, as well as mechanisms pertaining to gut flora. Our expertise and integrated services will provide you with valuable insights into the mechanisms of ASD pathology, enabling the development of innovative therapies and diagnostics for ASD.
Fig. 2 The graphical abstract of potential pathology of autism spectrum disorder (ASD) investigated by multi‐omics methods. (Zhuang, H.; et al., 2024)
Preclinical Screening and Evaluation Services for Anti-Autism Spectrum Disorder Drugs
Ace Therapeutics can provide biopharmaceutical companies and other drug discovery organizations with services to develop drugs for autism spectrum disorders. This service covers the entire process of drug research and drug development. The development of anti-autism spectrum disorder drugs requires the design, synthesis, screening, optimization, and standardization of molecular combinations to find the most effective and safest drugs. This requires a high level of skill, expense, and resources. Our drug development services can help you reduce costs and risks.
Diagnostic Method Development Services for Autism Spectrum Disorders
Timely identification and diagnosis play a critical role in promoting early intervention and prognostic outcomes in ASD. Measurable laboratory biomarkers can provide earlier and more reliable diagnosis and can further differentiate the autism spectrum based on common pathophysiological features, allowing for individualized treatment and response monitoring, and increasing the chances of success of future drug development programs.
Ace Therapeutics assists clients in identifying and characterizing quantifiable laboratory markers for precise ASD diagnosis through untargeted histology and targeted ASD diagnostic marker studies. We provide strategies for the development of bio-diagnostic markers for ASD, with a focus on the following areas:
Genetic testing, proteomics, and metabolomics were employed to screen blood, urine, and saliva samples for genes, proteins, peptides, and metabolites that have the potential to be diagnostic markers for ASD.
The targeted validation and detection of diagnostic markers, especially using some high‐throughput methods (e.g., targeted proteomics, metabolomics).
The following table summarizes targeted metabolomics-based research on potential biomarkers for autism spectrum disorders (ASD).
Sample | Method | Related metabolites | Metabolic process involved |
---|---|---|---|
Blood | GC-MS, LC-HRMS | Decreased a: homocitrulline, citric acid, lactic acid, heptadecanoic acid, myristic acid Increased a: aspartic acid, serine, glutamic acid, glutaric acid, soleucine acid, 2-hydroxyvaleric, 3-aminoisobutyric acid, 5-hydroxynorvaline |
Mitochondrial dysfunction, abnormal gut microbiome metabolism |
Blood | LC-MS/MS | Decreased b: FL, G-H1, NFK Increased b: CMA, AASA, GSA, arginine, glutamic |
Abnormal protein glycosylation, protein oxidative metabolism |
Blood | Ion exchange chromatography | Decreased b: glutamate, serine, ornithine, proline | Glutamate neurotransmission, gastrointestinal abnormalities |
Blood | MS/MS | Decreased a: free carnitine, glutaricyl carnitine, octyl carnitine, 24 carbonyl carnitine, carnosyl carnitine | Mitochondrial dysfunction, abnormal fatty acid metabolism |
Blood | LC-MS/MS, MRM | Decreased a: leucine, isoleucine, valine Increased a: glutamine, glycine, ornithine |
Protein synthesis, neurotransmission, AA/BCAA metabolism |
Blood | LC-MS/MS | Decreased b: Nε-fructosyl-lysine Increased b: Nω-carboxymethylarginine, Nε-(1-carboxyethyl) lysine, glutamic semialdehyde, 3-nitrotyrosineα-aminoadipic semialdehyde |
Energy metabolism, amino acid neurotransmitter metabolism, branched-chain amino acid metabolism, nicotinamide metabolism, aminoacyl tRNA biosynthesis |
Blood | LC-MS/MS | Decreased b: L-glutamate, pyridoxamine, O-phospho-4-hydroxy-L-threonine, L-aspartate, 4-pyridoxate, phosphatidylethanolamine, 2-oxoglutaramate Increased b: L-glutamine, creatineacetylglycine, serylserine, 1-acyl-sn-glycero3phosphocholine, ornithine, phosphatidylserine |
Mitochondrial dysfunction, oxidative stress, energy metabolism, amino acid, vitamin, lipid metabolism |
Urine | GC-MS | Increased a: urine homovanillic acid, vanilla mandelic acid | Neurotransmitter metabolism, visual perception/memory, repetitive behavior, emotional disorders |
Urine | 1H-13C NMR | Decreased b: creatine, 3-methylhistidine Increased b: glycine, taurine, succinate, β-alanine |
Taurine and succinic acid |
Urine | GC-MS | Decreased b: 1H-indole-3-acetate, phosphate, palmitate, stearate, 3-methyladipate, hippurate, vanillylhydracrylate, 4-hydroxyphenyl-2-hydroxyacetate, 3-hydroxyphenylacetate | Intestinal bacteria microbial pathways |
Urine | 1H-NMR, 1H-13C HSQC-NMR | Decreased b: glutamate, creatine, 3-methylhistidine Increased b: succinate |
Energy metabolism disorder, mitochondrial dysfunction, amino acid metabolism of gut microbiota |
Urine | LC-MS/MS | Decreased a: Lys, Thr, Car, Pro, EtN, Hcy, Aad, Cit, Ans, 5Ava, Asp Increased a: MetS, Harg, 3MHis, Cr, Arg, 5HT, Hyp |
Oxidative stress, abnormal ornithine cycle, abnormal lysine metabolism, abnormal 5HT metabolism, E/I balance |
Our research focuses on immune/inflammation-related biomarkers, oxidative stress-related biomarkers, and mitochondria-related diagnostic markers.
Our approach involves the discovery and identification of ASD-associated biomarkers through comprehensive gut microbial analysis and monitoring of microbial metabolites in feces. Additionally, we monitor gut microbial metabolism in blood and urine, offering an alternative approach to the early diagnosis of ASD.
Ace Therapeutics can provide a full range of support to pharmaceutical companies and research institutions to help them approve anti-autism spectrum disorder drugs as soon as possible. If you are interested in our services, please contact us to learn how we can support you in your project.
Enter your E-mail and receive the latest news from us